Published in J Clin Microbiol on June 18, 2008
Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and reliable identification of clinical yeast isolates. J Clin Microbiol (2009) 3.45
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol (2010) 2.89
In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother (2010) 1.88
The airway microbiota in cystic fibrosis: a complex fungal and bacterial community--implications for therapeutic management. PLoS One (2012) 1.80
In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol (2009) 1.60
The Genomic Aftermath of Hybridization in the Opportunistic Pathogen Candida metapsilosis. PLoS Genet (2015) 1.48
Candida guilliermondii and other species of candida misidentified as Candida famata: assessment by vitek 2, DNA sequencing analysis, and matrix-assisted laser desorption ionization-time of flight mass spectrometry in two global antifungal surveillance programs. J Clin Microbiol (2012) 1.47
Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida. J Clin Microbiol (2011) 1.29
In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study. J Clin Microbiol (2012) 1.28
Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital. J Clin Microbiol (2009) 1.27
Candida palmioleophila: characterization of a previously overlooked pathogen and its unique susceptibility profile in comparison with five related species. J Clin Microbiol (2010) 1.20
Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia. Antimicrob Agents Chemother (2011) 1.17
Identification and Susceptibility Profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates. J Clin Microbiol (2008) 1.10
In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. Antimicrob Agents Chemother (2010) 1.08
Evolution of mating within the Candida parapsilosis species group. Eukaryot Cell (2011) 1.06
Sequence and analysis of the genome of the pathogenic yeast Candida orthopsilosis. PLoS One (2012) 0.98
Evaluation of matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry for identification of Candida parapsilosis, C. orthopsilosis and C. metapsilosis. Eur J Clin Microbiol Infect Dis (2011) 0.97
Assessment of two new molecular methods for identification of Candida parapsilosis sensu lato species. J Clin Microbiol (2011) 0.97
Epidemiology and echinocandin susceptibility of Candida parapsilosis sensu lato species isolated from bloodstream infections at a Spanish university hospital. J Antimicrob Chemother (2012) 0.96
Pyrosequencing analysis of 20 nucleotides of internal transcribed spacer 2 discriminates Candida parapsilosis, Candida metapsilosis, and Candida orthopsilosis. J Clin Microbiol (2009) 0.95
Genetic diversity of medically important and emerging Candida species causing invasive infection. BMC Infect Dis (2015) 0.95
Candida parapsilosis and the neonate: epidemiology, virulence and host defense in a unique patient setting. Expert Rev Anti Infect Ther (2012) 0.95
Evaluation of Luminex xTAG fungal analyte-specific reagents for rapid identification of clinically relevant fungi. J Clin Microbiol (2011) 0.93
Genome comparison of Candida orthopsilosis clinical strains reveals the existence of hybrids between two distinct subspecies. Genome Biol Evol (2014) 0.93
Genotypic and phenotypic properties of Candida parapsilosis sensu strictu strains isolated from different geographic regions and body sites. BMC Microbiol (2010) 0.92
Epidemiology of invasive fungal infections in the mediterranean area. Mediterr J Hematol Infect Dis (2011) 0.89
Assessment of accuracy of identification of pathogenic yeasts in microbiology laboratories in the United kingdom. J Clin Microbiol (2012) 0.82
Identification and differentiation of Candida parapsilosis complex species by use of exon-primed intron-crossing PCR. J Clin Microbiol (2014) 0.82
Rapid identification of medically important Candida isolates using high resolution melting analysis. PLoS One (2015) 0.81
Analysis of inteins in the Candida parapsilosis complex for simple and accurate species identification. J Clin Microbiol (2013) 0.80
Multiple Origins of the Pathogenic Yeast Candida orthopsilosis by Separate Hybridizations between Two Parental Species. PLoS Genet (2016) 0.79
Characterization of Candida parapsilosis complex strains isolated from invasive fungal infections. Eur J Clin Microbiol Infect Dis (2011) 0.79
Effect of usnic acid on Candida orthopsilosis and C. parapsilosis. Antimicrob Agents Chemother (2011) 0.77
A case of Candida orthopsilosis associated septic arthritis in a patient with Systemic Lupus Erythematosus (SLE). Med Mycol Case Rep (2014) 0.75
Postantifungal Effect of Micafungin against the Species Complexes of Candida albicans and Candida parapsilosis. PLoS One (2015) 0.75
Susceptibility and molecular characterization of Candida species from patients with vulvovaginitis. Braz J Microbiol (2016) 0.75
Evolution and Application of Inteins in Candida species: A Review. Front Microbiol (2016) 0.75
Comparison of four molecular approaches to identify Candida parapsilosis complex species. Mem Inst Oswaldo Cruz (2017) 0.75
MTL genotypes, phenotypic switching, and susceptibility profiles of Candida parapsilosis species group compared to Lodderomyces elongisporus. PLoS One (2017) 0.75
Candida parapsilosis sensu lato in pediatric patients. Identification of cryptic species and antifungal susceptibility testing. Antimicrob Agents Chemother (2017) 0.75
Risk of Fungal Infection to Dental Patients. ScientificWorldJournal (2017) 0.75
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother (2003) 5.48
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol (2005) 3.93
The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis (1999) 3.92
In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol (2007) 3.57
Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis (1999) 3.39
Genotypic identification and characterization of species and strains within the genus Candida by using random amplified polymorphic DNA. J Clin Microbiol (1992) 3.27
Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother (2005) 2.75
Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol (2003) 2.70
Three distinct genotypes within Candida parapsilosis from clinical sources. J Clin Microbiol (1995) 2.13
Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J Clin Microbiol (2006) 2.00
One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol (2007) 1.87
Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol (2006) 1.81
Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol (2004) 1.66
High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis (1999) 1.57
Genomic heterogeneity in the yeast Candida parapsilosis. Curr Genet (1993) 1.53
Lodderomyces elongisporus masquerading as Candida parapsilosis as a cause of bloodstream infections. J Clin Microbiol (2007) 1.42
Phylogeny and evolution of medical species of Candida and related taxa: a multigenic analysis. J Clin Microbiol (2004) 1.38
Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol (2005) 1.37
Confirmation of the distinct genotype groups within the form species Candida parapsilosis. J Clin Microbiol (1998) 1.36
Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol (2008) 1.36
Genotyping of Candida orthopsilosis clinical isolates by amplification fragment length polymorphism reveals genetic diversity among independent isolates and strain maintenance within patients. J Clin Microbiol (2007) 1.32
Clinical and microbiological aspects of candidemia due to Candida parapsilosis in Brazilian tertiary care hospitals. Med Mycol (2006) 1.29
Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob Agents Chemother (2008) 1.29
Cloning and characterization of a complex DNA fingerprinting probe for Candida parapsilosis. J Clin Microbiol (2001) 1.27
Occurrence and genetic variability of Candida parapsilosis sensu lato in Hungary. J Med Microbiol (2007) 1.10
Secular trends of candidemia in a large tertiary-care hospital from 1988 to 2000: emergence of Candida parapsilosis. Infect Control Hosp Epidemiol (2005) 1.03
Strain characterization of Candida parapsilosis fungemia by molecular typing methods. Eur J Clin Microbiol Infect Dis (2000) 0.87
Molecular identification of Candida orthopsilosis isolated from blood culture. Mycopathologia (2008) 0.85
Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med (2002) 5.39
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Methicillin-resistant Staphylococcus aureus (MRSA) strain ST398 is present in midwestern U.S. swine and swine workers. PLoS One (2008) 4.60
Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis (2009) 4.59
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis (2013) 4.14
Epidemiology of invasive mycoses in North America. Crit Rev Microbiol (2010) 4.06
Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother (2009) 3.82
Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol (2007) 3.51
Has antifungal susceptibility testing come of age? Clin Infect Dis (2002) 3.39
Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis (2004) 3.20
Detection and treatment of bloodstream infection: laboratory reporting and antimicrobial management. J Clin Microbiol (2003) 3.17
In Candida albicans, white-opaque switchers are homozygous for mating type. Genetics (2002) 2.96
Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis (2003) 2.54
Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol (2005) 2.26
Adverse outcomes associated with Contact Precautions: a review of the literature. Am J Infect Control (2009) 2.21
Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob Agents Chemother (2010) 2.03
Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother (2011) 2.01
Improving methicillin-resistant Staphylococcus aureus surveillance and reporting in intensive care units. J Infect Dis (2006) 1.97
A multicenter intervention to prevent catheter-associated bloodstream infections. Infect Control Hosp Epidemiol (2006) 1.93
Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.). Emerg Infect Dis (2013) 1.84
Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn Microbiol Infect Dis (2002) 1.83
Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis (2007) 1.80
Determining the clinical significance of coagulase-negative staphylococci isolated from blood cultures. Infect Control Hosp Epidemiol (2005) 1.78
Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J Clin Microbiol (2003) 1.75
Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol (2010) 1.69
Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J Antimicrob Agents (2011) 1.69
Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother (2010) 1.61
Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn Microbiol Infect Dis (2011) 1.57
Enhanced identification of postoperative infections among inpatients. Emerg Infect Dis (2004) 1.56
Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans. Antimicrob Agents Chemother (2004) 1.49
Flucytosine resistance is restricted to a single genetic clade of Candida albicans. Antimicrob Agents Chemother (2004) 1.49
Candida guilliermondii and other species of candida misidentified as Candida famata: assessment by vitek 2, DNA sequencing analysis, and matrix-assisted laser desorption ionization-time of flight mass spectrometry in two global antifungal surveillance programs. J Clin Microbiol (2012) 1.47
Clinical significance of positive cranial bone flap cultures and associated risk of surgical site infection after craniotomies or craniectomies. J Neurosurg (2011) 1.45
Improving the assessment of vancomycin-resistant enterococci by routine screening. J Infect Dis (2006) 1.44
Homozygosity at the Candida albicans MTL locus associated with azole resistance. Microbiology (2002) 1.43
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). J Clin Microbiol (2006) 1.43
First description of Klebsiella pneumoniae harboring CTX-M beta-lactamases (CTX-M-14 and CTX-M-3) in Taiwan. Antimicrob Agents Chemother (2002) 1.42
Lodderomyces elongisporus masquerading as Candida parapsilosis as a cause of bloodstream infections. J Clin Microbiol (2007) 1.42
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis (2011) 1.42
Wide variability in the use of antimicrobial lock therapy and prophylaxis among infectious diseases consultants. Infect Control Hosp Epidemiol (2010) 1.40
Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009. Antimicrob Agents Chemother (2011) 1.38
Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol (2005) 1.37
Tiamulin activity against fastidious and nonfastidious veterinary and human bacterial isolates: initial development of in vitro susceptibility test methods. J Clin Microbiol (2002) 1.37
Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis (2002) 1.36
Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. Antimicrob Agents Chemother (2012) 1.31
Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates. Antimicrob Agents Chemother (2013) 1.29
Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immune Defic Syndr (2002) 1.29
Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida. J Clin Microbiol (2011) 1.29
Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme. Mycopathologia (2012) 1.26
Preventing MRSA infections: finding it is not enough. JAMA (2008) 1.26
Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae, Taiwan. Emerg Infect Dis (2002) 1.25
Strain-relatedness of methicillin-resistant Staphylococcus aureus isolates recovered from patients with repeated infection. Clin Infect Dis (2008) 1.24
Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial. Ann Intern Med (2005) 1.23
Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009). Diagn Microbiol Infect Dis (2010) 1.21
Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy. Diagn Microbiol Infect Dis (2003) 1.21
Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature. J Clin Microbiol (2009) 1.21
Public reporting of health care-associated surveillance data: recommendations from the healthcare infection control practices advisory committee. Ann Intern Med (2013) 1.16
Analysis of ALS5 and ALS6 allelic variability in a geographically diverse collection of Candida albicans isolates. Fungal Genet Biol (2007) 1.16
Rapid detection of antibiotic-resistant organism carriage for infection prevention. Clin Infect Dis (2013) 1.16
Dispersal of Staphylococcus aureus into the air associated with a rhinovirus infection. Infect Control Hosp Epidemiol (2005) 1.15
Decreasing prevalence of beta-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States. Antimicrob Agents Chemother (2005) 1.15
Drug resistance is not directly affected by mating type locus zygosity in Candida albicans. Antimicrob Agents Chemother (2003) 1.15
In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. J Clin Microbiol (2013) 1.14
Rapid detection of antimicrobial-resistant organism carriage: an unmet clinical need. J Clin Microbiol (2004) 1.12
Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. Antimicrob Agents Chemother (2008) 1.11
To screen or not to screen for methicillin-resistant Staphylococcus aureus. J Clin Microbiol (2010) 1.11
Fluoroquinolone resistance in Streptococcus pyogenes. Clin Infect Dis (2003) 1.11
Improving typeability of multiple bacterial species using pulsed-field gel electrophoresis and thiourea. Diagn Microbiol Infect Dis (2003) 1.11
Identification and Susceptibility Profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates. J Clin Microbiol (2008) 1.10
Evaluation of postprescription review and feedback as a method of promoting rational antimicrobial use: a multicenter intervention. Infect Control Hosp Epidemiol (2012) 1.10
Evidence for recombination in Candida glabrata. Fungal Genet Biol (2005) 1.10
Molecular epidemiology of macrolide resistance in neonatal bloodstream isolates of group B streptococci. J Clin Microbiol (2003) 1.09
A prospective study of outcomes, healthcare resource utilization, and costs associated with postoperative nosocomial infections. Infect Control Hosp Epidemiol (2006) 1.09
Are United States hospitals following national guidelines for the analysis and presentation of cumulative antimicrobial susceptibility data? Diagn Microbiol Infect Dis (2004) 1.09
Evaluation of three molecular typing techniques for nonfermentative Gram-negative bacilli. Infect Control Hosp Epidemiol (2004) 1.08
Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis (2010) 1.06